AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Activity: Griseofulvin works by inhibiting the growth of fungi, specifically dermatophytes, which are responsible for causing various fungal infections of the skin, hair, and nails.
Treatment of Dermatophytosis: Griseofulvin is commonly used to treat dermatophytosis, also known as ringworm, which can affect the skin, scalp, and nails. It is effective against infections caused by fungi such as Trichophyton, Microsporum, and Epidermophyton.
Fungal Nail Infections: Griseofulvin is particularly useful in the treatment of fungal nail infections (onychomycosis), which can be challenging to treat due to the slow growth of nails and the difficulty of topical antifungal agents penetrating the nail plate.
Topical and Oral Formulations: Griseofulvin is available in both topical and oral formulations. Oral griseofulvin is typically used for systemic fungal infections, while topical formulations are applied directly to the affected area for localized infections.
Duration of Treatment: Treatment with griseofulvin may be prolonged, often lasting several weeks to months, depending on the severity and location of the fungal infection. Compliance with the prescribed treatment regimen is essential to achieve a successful outcome.
Adverse Effects: Common side effects of griseofulvin may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. Other adverse effects may include headache, dizziness, fatigue, and allergic reactions such as rash or itching.
Drug Interactions: Griseofulvin may interact with certain medications, including oral contraceptives, warfarin, phenobarbital, and cyclosporine, among others. It can decrease the effectiveness of hormonal contraceptives and increase the metabolism of other drugs, potentially leading to reduced efficacy or toxicity.
Liver Function Monitoring: Patients taking griseofulvin may require periodic monitoring of liver function tests, as the medication can rarely cause liver toxicity or hepatitis. Individuals with pre-existing liver disease should use griseofulvin with caution and under close medical supervision.
Photosensitivity: Griseofulvin may increase the risk of sunburn or photosensitivity reactions. Patients should be advised to avoid excessive sun exposure and use sun protection measures, such as wearing protective clothing and sunscreen, while taking the medication.
Contraindications: Griseofulvin is contraindicated in individuals with known hypersensitivity to the drug or its components, as well as in pregnant women or women who may become pregnant, due to the risk of teratogenic effects.
Pediatric Use: Griseofulvin is commonly used in pediatric patients for the treatment of fungal infections, particularly tinea capitis (scalp ringworm). Dosing may vary based on the child's age, weight, and the severity of the infection.
Effectiveness: Griseofulvin is generally effective in treating fungal infections when used as prescribed. However, it may not be suitable for all types of fungal infections, and healthcare providers may consider alternative antifungal agents based on the specific diagnosis and patient factors.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Simiaoa sunii | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
0 | 1 | Wujia chipingensis | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
0 | 1 | Eubacterium ventriosum | species | Decreases |
0 | 1 | Faecalibacterium sp. IP-1-18 | species | Decreases |
0 | 1 | Ruminococcus bicirculans (ex Wegman et al. 2014) | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Clostridium sp. M62/1 | species | Decreases |
0 | 1 | Faecalibacterium sp. I3-3-33 | species | Decreases |
0 | 1 | Faecalibacterium sp. I4-3-84 | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Lachnospira eligens | species | Decreases |
0 | 1 | Oscillibacter hominis | species | Decreases |
0 | 1 | Roseburia intestinalis | species | Decreases |
0 | 1 | Clostridium sp. SY8519 | species | Decreases |
0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
0 | 1 | Coprococcus comes | species | Decreases |
0 | 1 | Wansuia hejianensis | species | Decreases |
0 | 1 | Intestinibaculum porci | species | Decreases |
0 | 1 | Faecalibacterium duncaniae | species | Decreases |
0 | 1 | Mageeibacillus indolicus | species | Decreases |
0 | 1 | Monoglobus pectinilyticus | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
ADHD | 0.6 | 0.6 | |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 0.5 | 0.7 | -0.4 |
Allergies | 1.8 | 0.4 | 3.5 |
Allergy to milk products | 0.8 | 0.6 | 0.33 |
Alopecia (Hair Loss) | 0.1 | -0.1 | |
Alzheimer's disease | 2 | 1.6 | 0.25 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.7 | 0.43 |
Ankylosing spondylitis | 1.3 | 0.3 | 3.33 |
Anorexia Nervosa | 0.1 | 0.6 | -5 |
Antiphospholipid syndrome (APS) | 0.8 | 0 | 0 |
Asthma | 1.5 | 0.4 | 2.75 |
Atherosclerosis | 1.2 | 0.3 | 3 |
Atrial fibrillation | 0.4 | 0.7 | -0.75 |
Autism | 1.4 | 2.2 | -0.57 |
Autoimmune Disease | 0.5 | 0.2 | 1.5 |
Barrett esophagus cancer | 0.2 | 0 | 0 |
benign prostatic hyperplasia | 0.5 | 0.1 | 4 |
Biofilm | 1.1 | 1.1 | |
Bipolar Disorder | 0.7 | 0.2 | 2.5 |
Brain Trauma | 0 | 0.3 | 0 |
Breast Cancer | 1.1 | 1.1 | |
Cancer (General) | 0.2 | 0.6 | -2 |
Carcinoma | 1.2 | 0.1 | 11 |
Celiac Disease | 1.1 | 0.2 | 4.5 |
Cerebral Palsy | 0.2 | 0.3 | -0.5 |
Chronic Fatigue Syndrome | 1.6 | 0.5 | 2.2 |
Chronic Kidney Disease | 0.8 | 0.3 | 1.67 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.4 | 1.5 |
Chronic Urticaria (Hives) | 1 | 0.3 | 2.33 |
Coagulation / Micro clot triggering bacteria | 1.2 | 0.2 | 5 |
Cognitive Function | 0.2 | 0.2 | 0 |
Colorectal Cancer | 2.8 | 1 | 1.8 |
Constipation | 0.6 | 0.2 | 2 |
Coronary artery disease | 1.2 | 0.5 | 1.4 |
COVID-19 | 1.9 | 1.2 | 0.58 |
Crohn's Disease | 2.9 | 1 | 1.9 |
Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
cystic fibrosis | 0.9 | 0.3 | 2 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 1.9 | 0.3 | 5.33 |
Denture Wearers Oral Shifts | 0.6 | 0.6 | |
Depression | 3 | 2.3 | 0.3 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.8 | 0.4 | 1 |
Endometriosis | 1.3 | 0.8 | 0.63 |
Eosinophilic Esophagitis | 0.2 | 0 | 0 |
Epilepsy | 1.8 | 0.3 | 5 |
erectile dysfunction | 0.8 | 0.8 | |
Fibromyalgia | 0.4 | 0.4 | 0 |
Functional constipation / chronic idiopathic constipation | 1.7 | 0.6 | 1.83 |
gallstone disease (gsd) | 1.2 | 0.4 | 2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0 | 0 |
Generalized anxiety disorder | 1.5 | 0.2 | 6.5 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0 | 0 | |
Gout | 0.2 | 0.2 | 0 |
Graves' disease | 0.1 | 0.3 | -2 |
Gulf War Syndrome | 0 | 0.3 | 0 |
Halitosis | 0.8 | 0 | 0 |
Hashimoto's thyroiditis | 0.8 | 0.2 | 3 |
Heart Failure | 1.9 | 0.2 | 8.5 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.4 | 0.4 | |
High Histamine/low DAO | 0.8 | 0.8 | |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.1 | 5 |
hyperglycemia | 1.2 | 0.2 | 5 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 0.8 | 1.1 | -0.38 |
Hypothyroidism | 0 | 0 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.4 | 0.4 | 0 |
Inflammatory Bowel Disease | 3.4 | 1.8 | 0.89 |
Insomnia | 0.2 | 0.4 | -1 |
Intelligence | 0.9 | 0.9 | |
Intracranial aneurysms | 0.4 | 0.4 | |
Irritable Bowel Syndrome | 2.2 | 0.6 | 2.67 |
ischemic stroke | 0.8 | 0.8 | 0 |
Liver Cirrhosis | 2.2 | 1.3 | 0.69 |
Long COVID | 1 | 0.8 | 0.25 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.5 | 0.1 | 4 |
Lymphoma | 0.5 | 0.5 | |
Mast Cell Issues / mastitis | 1 | 1 | |
ME/CFS with IBS | 0 | 0.3 | 0 |
ME/CFS without IBS | 0 | 0.2 | 0 |
membranous nephropathy | 0 | 0 | |
Menopause | 0 | 0.2 | 0 |
Metabolic Syndrome | 2.1 | 1.4 | 0.5 |
Mood Disorders | 2.3 | 1.7 | 0.35 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 1 | 0.7 | 0.43 |
Multiple system atrophy (MSA) | 0.4 | 0.4 | |
myasthenia gravis | 0.5 | 0.2 | 1.5 |
neuropathic pain | 0.7 | -0.7 | |
Neuropathy (all types) | 0.1 | 0.5 | -4 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 0.4 | 3.5 |
NonCeliac Gluten Sensitivity | 0.2 | 0.1 | 1 |
Obesity | 2.3 | 2.3 | 0 |
obsessive-compulsive disorder | 1.7 | 0.2 | 7.5 |
Osteoarthritis | 0.7 | 0.2 | 2.5 |
Osteoporosis | 0.8 | 0.2 | 3 |
pancreatic cancer | 0.5 | 0 | 0 |
Parkinson's Disease | 1.9 | 1.7 | 0.12 |
Polycystic ovary syndrome | 1.4 | 0.4 | 2.5 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0 | 0 | |
primary biliary cholangitis | 0 | 0.4 | 0 |
Primary sclerosing cholangitis | 0.4 | 0.2 | 1 |
Psoriasis | 0.9 | 0.4 | 1.25 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 0.8 | 0.75 |
Rosacea | 0.2 | -0.2 | |
Schizophrenia | 0.7 | 0.3 | 1.33 |
scoliosis | 0.7 | 0.1 | 6 |
Sjögren syndrome | 0.6 | 0.3 | 1 |
Sleep Apnea | 0.4 | 0.3 | 0.33 |
Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 1 | |
Stress / posttraumatic stress disorder | 1.4 | 0.4 | 2.5 |
Systemic Lupus Erythematosus | 1.2 | 0.6 | 1 |
Tic Disorder | 0 | 0 | |
Tourette syndrome | 0.1 | 0.1 | 0 |
Type 1 Diabetes | 1 | 0.3 | 2.33 |
Type 2 Diabetes | 2.1 | 2.1 | 0 |
Ulcerative colitis | 2.6 | 1.3 | 1 |
Unhealthy Ageing | 1.1 | 0.2 | 4.5 |
Vitiligo | 0.4 | 0.2 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]